Beyond Air Reports 107% FY26 Revenue Growth, Projects >110% CY27 Growth Amidst Nasdaq Compliance Efforts
XAIR sits 44% above its 52-week low of $0.335 on elevated volume (3.6× avg).
Summary
Beyond Air reported strong fiscal year 2026 revenue growth and issued optimistic guidance for 2027, projecting over 110% growth, which is critical as the company faces a Nasdaq delisting deadline and a going concern warning.
Key Events · Earnings and Guidance · XAIR
-
Strong Fiscal Year 2026 Revenue Growth
Beyond Air reported a 107% year-over-year increase in revenue to $7.7 million for the fiscal year ended March 31, 2026, with Q4 revenue up 66% to $1.9 million.
-
Optimistic Revenue Guidance for 2026 and 2027
The company projects $8 million in revenue for calendar year 2026 (15% growth) and $16-$18 million for calendar year 2027, representing over 110% year-over-year growth at the midpoint.
-
Potential Market Expansion with Second-Generation Product
Awaiting FDA approval for its second-generation LungFit PH system, which, if approved with a broader label, could increase the total addressable U.S. market by 4x to approximately $400 million and worldwide to over $1 billion.
-
Fiscal Year-End Change Approved
The Board of Directors approved changing the company's fiscal year-end from March 31 to December 31, effective December 31, 2026, with a nine-month transition period.
Analysis · XAIR · Industrial Applications And Services
Beyond Air reported strong fiscal year 2026 revenue growth of 107% to $7.7 million, with Q4 revenue up 66%. More significantly, the company provided revenue guidance of $8 million for calendar year 2026 (15% growth) and $16-$18 million for calendar year 2027, representing over 110% year-over-year growth. This optimistic outlook is contingent on the FDA approval of its second-generation LungFit PH system, which could expand the total addressable U.S. market by 4x to $400 million and worldwide to over $1 billion. This positive forward-looking guidance is crucial for the company, which recently received a Nasdaq delisting notice and a going concern warning in its 10-K filed on the same day. The Board also approved a change in the fiscal year-end from March 31 to December 31, effective December 31, 2026, to align with calendar year reporting.
At the time of this filing, XAIR was trading at $0.48 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6.3M. The 52-week trading range was $0.33 to $4.78. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.